DƯỢC LÍ Goodman & Gilman's The Pharmacological Basis of Therapeutics 12th, 2010

2002
INDEX
Atorvastatin (Cont.):
dosage of, required to achieve
reduction in LDL-C, 895t
pharmacokinetics of, 1816t
SLC transporters and, 102t
structure of, 893f
therapeutic uses of, 897
in children, 898
Atosiban, for prevention of preterm
labor, 1848
Atovaquone, 1398–1399
treatment regimen for, 1389t
ATP. See Adenosine triphosphate
(ATP)
ATP-binding cassette (ABC),
878
ATP-binding cassette (ABC) proteins,
89, 94, 94f, 96
in absorption, 105t–106t, 107
at blood-brain barrier, 104
crystal structure, 97
in distribution, 105t–106t
in elimination, 107
in excretion, 105t–106t
in intestine, 103
in kidneys, 103–104, 105t–106t
linked genetic diseases, 104t
in liver, 103–104, 105t–106t, 108
MRP family, 104
physiological roles of,
107–108
properties related to drug action,
103–108
substrate specificity of, 104
superfamily, 99–108
tissue distribution of, 103–107
ATP-mediated transport, 674
Atracurium
characteristics of, 264t
cholinergic receptors and, 206t
dosing of, 265t
structure of, 259f
Atrial depolarization, premature,
management of, 824t
Atrial fibrillation, 823, 830
drugs for
disopyramide, 839
flecainide, 840–841
quinidine, 843–844
sotalol, 845
ECG of, 825f
management of, 824t
rapid, angina pectoris with,
recommended treatment for,
769t
Atrial flutter, 822, 830
drugs for
disopyramide, 839
quinidine, 843–844
sotalol, 845
ECG of, 825f
management of, 824t
with variable AV conduction, ECG
of, 825f
Atrial natriuretic peptide, for asthma,
1046
Atrial natriuretic peptide (ANP), 695f
mechanism of action of, 695–696,
695f
site of action of, 695–696
and vasopressin secretion, 704
Atrial tachycardia
drug-induced, 821t
management of, 824t
Atrioventricular (AV) block
angina pectoris with, recommended
treatment for, 769t
drug-induced, 821t
Atrioventricular (AV) nodal re-entrant
tachycardia, 822, 822f
management of, 824t
Atrioventricular (AV) node
acetylcholine and, 220–221
in autonomic nervous system, 178t
Atropa belladonna, 226
Atropine
adrenergic receptors and, 206t
for anticholinestrase intoxication,
248, 249
cardiovascular therapeutic uses of,
233
central nervous system and, 230
chemistry of, 226–227
choline esters and, 223t
for diarrhea, 233
dose-related effects of, 226, 226t
eyes and, 228
gastrointestinal effects of, 226, 226t
history of, 226
mechanism of action of, 227
respiratory system and, 228
structure-activity relationship, 227
structure of, 227f
Atropine sulfate, as antidote, 86t
ATRYN (recombinant antithrombin), 860
Attention-deficit hyperactivity disorder
(ADHD)
dopamine receptor agonists and, 358
sympathomimetic agents for,
303–304
Atypical antipsychotics, 350–351, 359
mechanism of action, 407
Auerbach’s plexus. See Myenteric
plexus
Authority, to write prescriptions, 1880
Autism, antipsychotics for, 436
Autocoids
lipid-derived, 937
release of, histamine and, 914
Autonomic effector cells, 188–189
Autonomic ganglia, 189
neuromuscular blocking agents and,
262
Autonomic ground plexus, 176
Autonomic nervous system (ANS)
acetylcholine in, 172, 177f
anatomy of, 171–181, 173f
central connections, 172
co-transmission in, 213–214
divisions of peripheral, 172
effector organ responses to, 176
eye in, 178t
functions of, 171–181
somatic vs., 171
Autosomal recessive, 146–147
AV. See Atrioventricular (AV) node
AVAGE (tazarotene), 1810
AVANDIA (rosiglitazone), 1845
AVAPRO (irbesartan), 738
AVASTIN (bevacizumab), 1739, 1794
Avidin, 858
AVITA (tretinoin), 1810
Avobenzone, 1827
Axonal conduction, 182–183
Axosemide
pharmacology of, 683t
structure of, 683t
AYGESTIN (norethindrone), 1839t
Azacitidine, 1700
Azapropazone, 992
AZASITE (azithromycin), 1781t
Azathioprine, 994t, 1013–1014
in dermatology, 1820–1821
mechanism of action of, 1820t
metabolism of, 139
pharmacokinetics of, 1815t, 1816t
polymorphisms and response to, 161t
AZD829, 866
Azelaic acid
for acne, 1830
for hyperpigmentation, 1830
mechanism of action of, 1830
for rosacea, 1830
structure of, 1830
topical, for acne, 1817